Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer Article

Open Access Industry Collaboration International Collaboration

cited authors

  • Socinski, Mark A.; Waller, Cornelius F.; Idris, Tazeen; Bondarenko, Igor; Luft, Alexander; Beckmann, Katrin; Vishweswaramurthy, Ashwini; Loganathan, Subramanian; Donnelly, Charles; Hummel, Matthew A.; Shapiro, Roxann; Woods, Melody; Rao, Anita; Nayak, Vivek G.; Ranganna, Gopinath; Barve, Abhijit

authors

Publication Date

  • November 1, 2021

webpage

published in

category

keywords

  • MYL-1402O
  • bevacizumab
  • biosimilar
  • clinical trial
  • non-small-cell lung cancer

volume

  • 13